ClinicalTrials.gg
CompletedNCT04907162Updated Aug 24, 2022

Musculoskeletal Nociceptive Pain in Participants With Neuromuscular Disorders

An observational study in Pompe Disease (Late-onset), Myotonic Dystrophy Type 1 (DM1) and Myotonic Dystrophy Type 2, sponsored by LMU Klinikum. Completed at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-08-24.

Sponsored by LMU Klinikum · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
82
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Glycogen Storage Disease Type II with a site in Germany — 9 open to participants now, 13 under way, 3 of them phase 3. Glycogen Storage Disease Type II · Germany.

Enrollment
7th of 12
82 · median 89
Started
2021
with 2 others
Observational
12 of 34
5 open now
Registered
24th of 34
by date
Lead sponsor
5 of 34
LMU Klinikum

Among the 34 studies in Glycogen Storage Disease Type II with a site in Germany, this one is the 7th largest by enrollment of the 12 observational ones that give a count, is one of 3 that started in 2021, is one of 12 observational ones, and was the 24th registered.

Glycogen Storage Disease Type II

162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.

Browse Glycogen Storage Disease Type II studies →

Open to participants now

9 of the 34 studies in Glycogen Storage Disease Type II with a site in Germany are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Glycogen Storage Disease Type II with a site in Germany, or all of them as a file.
02

Study summary

The primary aim is to characterize the prevalence, severity and quality of musculoskeletal nociceptive pain in adult patients with neuromuscular disorders (NMD). The secondary objectives are to evaluate whether severity and distribution of muscle pain is associated with muscle function, and to assess whether muscle pain is associated with alterations of muscle elasticity and muscle stiffness. Results of patients with neuromuscular disorders will be compared to age- and gender-matched healthy volunteers. Approx. 70 patients with neuromuscular disorders and 20 healthy volunteers will be enrolled, including patients with the following neuromuscular disorders: histologically confirmed inclusion body myositis (IBM), genetically confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal muscular atrophy type 3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD), genetically confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). The duration of patient recruitment will be around 12 months.

Read the detailed description

The explorative, cross-sectional low-interventional pilot study evaluates the prevalence, severity and quality of musculoskeletal nociceptive pain in participants with defined neuromuscular disorders (NMD). Adult participants with the following neuromuscular disorders will be included: histologically confirmed inclusion body myositis (IBM), genetically confirmed late-onset Pompe disease (LOPD), genetically confirmed spinal muscular atrophy type 3 (SMA3), genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD) and genetically confirmed myotonic dystrophy type 1 or type 2 (DM1, DM2). 20 healthy participants will be enrolled as a control group. The Beck depression inventory fast screen (BDI-FS) will be used as a screening. If there is a possibility of major depression (with a BDI ≥4), patients will be excluded from the study. So only patients with BDI-FS score ≤3 at screening will be enrolled. Patients will be asked to complete the following validated disease-related and quality-of-life questionnaires: German Pain Inventory (module A and abbreviated module S and L and V), Brief Pain Inventory (BPI) and Fatigue Severity and Disability Scale (FSS). Demographic and disease related data will be obtained. A neuromuscular examination will be conducted. A clinical evaluation of muscle strength using the MRC-Scale (Medical Research Council-Scale) will be performed on both sides deltoid muscles, biceps brachii muscles, triceps brachii muscles, hip flexors, hip extensors, quadriceps femoris muscles, foot extensor and foot flexor muscles as well as axial muscles and neck flexors and extensors. The Quick Motor Function Test (QMFT) with 16 items will be performed to assess muscle and movement functions of the participants. To ensure a high level of objective measurement, muscle strength will also be assessed by using handheld dynamometry. The following muscle groups will be tested: arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion. A six-minute-walk test (6MWT) will be performed once. Additionally, first signs of muscle pain or muscle cramps will be recorded (including the quality and intensity of pain). The Borg scale to rate dyspnea will be administered before starting the 6MWT and after completing the 6MWT. For diagnosis of myofascial pain, a Pressure Pain Threshold test by using a pressure algometer is included for the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles until the patient feels any sensation of pain. Measurement of muscle stiffness, muscle tone, relaxation periods and viscoelasticity of selected muscles will be assessed by a myotonometer. Data collected in this study will be reported using summary tables, figures, and patient data listings. Differences between the patients and the healthy volunteers will be analyzed.

03

Conditions studied

  • Pompe Disease (Late-onset)
  • Myotonic Dystrophy Type 1 (DM1)
  • Myotonic Dystrophy Type 2
  • Spinal Muscular Atrophy Type 3
  • Inclusion Body Myositis, Sporadic
  • Facioscapulohumeral Muscular Dystrophy 1
  • Healthy

Keywords

  • nociceptive pain
  • musculoskeletal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Approximately 70 patients with defined NMD (see inclusion criteria) will be enrolled. For a control group, 20 healthy volunteers will be enrolled. All patients must be ≥ 18 years of age.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is willing and able to provide signed .
  • The participant is able and willing to perform study-related assessments.
  • The participant is ≥18 years of age
  • The participant has one of the following diagnoses:

    • confirmed inclusion body myositis (IBM), or
    • genetically confirmed late-onset Pompe disease (LOPD), or
    • genetically confirmed spinal muscular atrophy type 3 (SMA3), or
    • genetically confirmed myotonic dystrophy type 1, or
    • genetically confirmed myotonic dystrophy type 2, or
    • genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD).

Exclusion criteria

Exclusion Criteria

  • The participant is participating in another clinical study or using an treatment.
  • The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study.
  • The participant has currently a severe depression, assessed by the Beck depression inventory fast screen (BDI-FS) with a score ≥ 4
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
82 participants (actual)
Patient registry
No

Groups and cohorts

  • Neuromuscular disease (NMD) Patients

    The patient has one of the following neuromuscular diagnoses: 1. histologically (muscle biopsy) confirmed inclusion body myositis (IBM), or 2. genetically confirmed late-onset Pompe disease (LOPD), or 3. genetically confirmed spinal muscular atrophy type 3 (SMA3), or 4. genetically confirmed myotonic dystrophy type 1, or 5. genetically confirmed myotonic dystrophy type 2, or 6. genetically confirmed facio-scapulo-humeral muscle dystrophy (FSHD).

    Diagnostic Test: Beck depression inventory fast screen · Diagnostic Test: German Pain Inventory · Diagnostic Test: Brief Pain Inventory · Diagnostic Test: Fatigue Severity and Disability Scale (FSS) · Diagnostic Test: Quick Motor Function Test · Diagnostic Test: Handheld Dynamometry (HHD) · Diagnostic Test: Six-minute walk test (6MWT) · Diagnostic Test: Pressure pain threshold · Diagnostic Test: Myotonometer Assessment · Diagnostic Test: Vital signs · Diagnostic Test: Borg Scale

  • Healthy control

    no known neuromuscular disorder

    Diagnostic Test: Beck depression inventory fast screen · Diagnostic Test: German Pain Inventory · Diagnostic Test: Brief Pain Inventory · Diagnostic Test: Fatigue Severity and Disability Scale (FSS) · Diagnostic Test: Quick Motor Function Test · Diagnostic Test: Handheld Dynamometry (HHD) · Diagnostic Test: Six-minute walk test (6MWT) · Diagnostic Test: Pressure pain threshold · Diagnostic Test: Myotonometer Assessment · Diagnostic Test: Vital signs · Diagnostic Test: Borg Scale

Interventions

  • Diagnostic testBeck depression inventory fast screen

    Beck depression inventory fast screen questionnaire to detect severe depression for eligibility.

    Also known as: BDI-FS

  • Diagnostic testGerman Pain Inventory

    German Pain Inventory questionnaire for evaluation of pain. Module A, abbreviated questions of module S (sociodemographic questions S1, S2, S3, S4, S5 and S8) and module L (quality of life) and V (therapies) will be used.

    Also known as: Deutscher Schmerzfragebogen (DSF)

  • Diagnostic testBrief Pain Inventory

    Validated questionnaire for pain.

    Also known as: BPI

  • Diagnostic testFatigue Severity and Disability Scale (FSS)

    Validated questionnaire for perceived fatigue

    Also known as: FSS

  • Diagnostic testQuick Motor Function Test

    An evaluator observes the performance of a patient and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). A total score is obtained by adding the scores of all items and ranges between 0 and 64 points.

    Also known as: QMFT

  • Diagnostic testHandheld Dynamometry (HHD)

    To ensure a high level of objective measurement, muscle strength will also be assessed by handheld dynamometry. The following muscle groups will be tested: Arm abduction, elbow flexion, elbow extension, hip flexion, hip extension, knee extension, knee flexion, foot extension, foot flexion.

    Also known as: HHD

  • Diagnostic testSix-minute walk test (6MWT)

    It is a sub-maximal exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity.

    Also known as: 6MWT

  • Diagnostic testPressure pain threshold

    For diagnosis of myofascial pain, pressure algometers are designed and conventionally used to measure deep pressure pain thresholds or tenderness resistance (Park, Kim et al. 2011), and the reliability of pressure pain thresholds according to raters or measurement frequencies has been proven to be relatively high (Chung, Um et al. 1992). The threshold is then determined as the arithmetic mean of the 3 series (in kPa). The measurement will be stopped immediately as the patient feels sensations of "burning", "stinging", "drilling" or "aching. Pressure algometry measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.

    Also known as: PPT

  • Diagnostic testMyotonometer Assessment

    Muscle stiffness, muscle tone, relaxation periods and viscoelasticity will be assessed by a myotonometer of selected muscles (non-invasive measurement). The method of measurement consists of recording damped natural oscillation of soft biological tissue in the form of an acceleration signal and the subsequent simultaneous computation of the parameters of State of Tension, Biomechanical and Viscoelastic properties. Measurements will be performed on the trapezius, deltoid and supraspinatus muscles, the rectus femoris muscles, and the tibialis anterior muscles.

  • Diagnostic testVital signs

    Vital signs (blood pressure, heart rate, respiratory rate) will be measured before and after the six-Minute-Walk-Test (6MWT).

    Also known as: Vital parameters (VP)

  • Diagnostic testBorg Scale

    the Borg scale will be assessed, which is a self-reported questionnaire designed to subjectively assess dyspnea and exertion during activity (Borg 1982). The Borg scale rates dyspnea on a scale of 0 to 10 incorporating nonlinear spacing of verbal descriptors of the level of intensity of dyspnea. A higher Borg score indicates more severe dyspnea. The Borg scale will be administered before starting the 6MWT (≤ 5 minutes) and after completing the 6MWT (≤ 5 minutes).

06

What researchers measure

Primary outcomes

  1. Prevalence of musculoskeletal pain in defined neuromuscular diseases

    The primary aim is to characterize the prevalence of musculoskeletal pain in adult patients with neuromuscular disorders (NMD).

    Time frame: Only at baseline visit

Secondary outcomes

  1. Association between musculoskeletal pain and muscle function, assessed by Medical research council (MRC) grading (0-5)

    Assessed by Medical research council (MRC) grading (0-5)

    Time frame: Only at baseline visit

  2. Association between musculoskeletal pain and muscle function, assessed by quick motor function test (QMFT)

    Assessed by quick motor function test (QMFT)

    Time frame: Only at baseline visit

  3. Association between musculoskeletal pain and muscle function, assessed by Pressure Pain Threshold (PPT)

    Assessed by Pressure Pain Threshold (PPT)

    Time frame: Only at baseline visit

  4. Association between musculoskeletal pain and muscle function, assessed by a Myotonometer

    Assessed by a Myotonometer (incl. relaxation time, stiffness, muscle tone, relaxation periods and viscoelasticity)

    Time frame: Only at baseline visit

  5. Assessment of Questionnaire: Beck depression inventory fast screen

    Association between Depression and musculoskeletal pain

    Time frame: Only at baseline visit

  6. Assessment of Questionnaire: Brief Pain Inventory

    Association between Depression and musculoskeletal pain

    Time frame: Only at baseline visit

  7. Assessment of Questionnaire: Fatigue Severity Scale (FSS)

    Association between Depression and musculoskeletal pain

    Time frame: Only at baseline visit

  8. Characterization of musculoskeletal pain (quality and severity) assessed by the German Pain Questionnaire

    Characterization of quality and severity of musculoskeletal pain

    Time frame: Only at baseline visit

  9. Characterization of musculoskeletal pain (quality and severity) assessed by the Brief Pain Inventory (BPI)

    Characterization (quality and severity) of musculoskeletal pain

    Time frame: Only at baseline visit

07

Study locations

1 site
  • Friedrich-Baur-Institute
    München, Bavaria 80336, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Aug 2022, 16 months.

Of 29 observational studies under Glycogen Storage Disease Type II, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 33. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
May 28, 2021
StartActual
Apr 15, 2021
Primary completionActual
Aug 15, 2022
CompletionActual
Aug 15, 2022
Last update
Aug 24, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04907162
Lead sponsor
LMU Klinikum
Responsible party
Prof. Dr. Benedikt Schoser (Clinical Professor, LMU Klinikum) — Principal investigator
First posted
May 28, 2021
Start date
Apr 15, 2021
Primary completion
Aug 15, 2022
Completion
Aug 15, 2022
Last update
Aug 24, 2022

Study contacts

Stephan Wenninger, PD Dr. med.
principal investigator · Neurologist

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion